Prognostic significance of the expression of GFRα1, GFRα3 and Syndecan-3, Proteins binding ARTEMIN, In mammary carcinoma by Wu, Z.-S. et al.
Wu et al. BMC Cancer 2013, 13:34
http://www.biomedcentral.com/1471-2407/13/34RESEARCH ARTICLE Open AccessPrognostic significance of the expression of
GFRα1, GFRα3 and Syndecan-3, proteins binding
ARTEMIN, in mammary carcinoma
Zheng-Sheng Wu1,2, Vijay Pandey3, Wen-Yong Wu4, Shan Ye2, Tao Zhu1* and Peter E Lobie3,5*Abstract
Background: Artemin (ARTN) has been implicated in promoting oncogenicity, tumor growth and invasiveness in
diverse human malignancies. However, the clinical and prognostic significance of upstream ligand binding
components, potentially mediating ARTN oncogenicity, largely remain to be determined.
Methods: We determined the mRNA and protein expression of three proteins demonstrated to bind ARTN, namely
GFRα1, GFRα3 and Syndecan-3 (SDC3), in benign breast disease and mammary carcinoma by in situ hybridization
and immunohistochemistry, respectively. Their prognostic significance combined with ARTN expression was also
investigated in mammary carcinoma.
Results: The expression of GFRα1 and GFRα3, but not SDC3, was significantly increased in mammary carcinoma
and positively associated with tumor lymph node metastases, higher clinical stage and HER-2 positivity. Moreover,
both GFRα1 and GFRα3 expression were significantly associated with survival outcome of patients with mammary
carcinoma by univariate and multivariate analyses, whereas expression of SDC3 was not. Co-expression of ARTN
with either GFRα1 or GFRα3, but not SDC3, produced synergistic increases in the odds ratio for both relapse-free
and overall survival in patients with mammary carcinoma. Furthermore, significant association of GFRα1 and GFRα3
expression with survival outcome observed herein were restricted to ER negative or HER-2 negative mammary
carcinoma.
Conclusions: The expression of GFRα1 and/or GFRα3, especially when combined with ARTN expression, may be
useful predictors of disease progression and outcome in specific subtypes of mammary carcinoma.
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Artemin (ARTN) is a growth factor belonging to the
glial cell line-derived neurotrophic factor (GDNF) family
of ligands (GFL) comprised of 4 members including
GDNF, neurturin and persephin. In addition to its
described neurotrophic role [1-3], ARTN has also been
implicated in promoting oncogenicity, tumor growth and
invasiveness in diverse human malignancies, including* Correspondence: zhut@ustc.edu.cn; csipel@nus.edu.sg
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reproduction in any medium, provided the ormammary, endometrial, esophageal, lung and pancreatic
carcinoma [4-10].
In mammary carcinoma (MC), increased expression of
ARTN has been observed compared to normal tissue
and expression of ARTN in MC predicted residual dis-
ease after chemotherapy, metastasis, relapse, and death
[5]. It has been reported that forced expression of ARTN
promotes tumor growth by increased proliferation and
survival [5,7,8]. Furthermore, ARTN promotes epithelial
to mesenchymal transition and angiogenesis and
enhances cancer stem cell like behaviour in ER-negative
MC (ER-MC) carcinoma cells resulting in metastatic dis-
semination [5,11-13]. Moreover increased ARTN expres-
sion predicts poor survival of patients with ER-positve
MC (ER +MC) treated with tamoxifen and forced. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[14]. The downstream signaling pathways by which
ARTN promotes cell survival, oncogenicity, drug resist-
ance [6,7,14] and metastases [11] have been reported.
However, the prognostic significance of upstream lig-
and binding components, potentially mediating ARTN
oncogenicity in mammary carcinoma, remain to be
determined.
GFL family members were initially thought to signal
via high affinity preferential interaction with one or
more of the GDNF receptor α family (GFRα) com-
prising GFRα1-4 [1-3]. The GFL- GFRα complex then
binds to and activates the transmembrane RET recep-
tor tyrosine kinase [4] which propagates cellular sig-
naling. However, GFLs are promiscuous and interact
with multiple GFRα family members, ARTN having
been reported to bind and activate both GFRα1 and
GFRα3 [3]. Moreover, GFLs have been reported to
bind to and/or activate distinct non-GFRα proteins
[15] and to function by both RET dependent and in-
dependent mechanisms [4,16,17]. Recently ARTN, as
well as GDNF, has been reported to activate signaling
through c-Src by binding to Syndecan-3 (SDC3) [18].
Increased GFRα1 expression has been previously
reported in MC and its expression is associated with
certain clinicopathologic features such as lymph node
metastases [4]. However, no correlation of expression
with survival outcome of patients was determined. To
date, the expression and prognostic significance of
GFRα3 and SDC3, the two other receptor proteins
binding ARTN in MC has not been reported.
In an attempt to determine which of the ARTN
binding proteins identified to date may mediate the
effects of ARTN in MC, we examined the mRNA and
protein expression of GFRα1, GFRα3 and SDC3 in
MC and examined the correlation of expression to
clinicopathologic features and patient survival out-
come, both by univariate and multivariate analyses.
Moreover, we correlated the combined expression of
ARTN and the various receptors with patient survival
outcome to determine which combination of ligand
and receptor may represent the functional complex
mediating mammary neoplastic progression.
Methods
Patients and specimens
The patient population consisted of 159 consecutive MC
patients and 26 consecutive patients with benign breast
disease (BBD) who underwent surgery at the First
Affiliated Hospital of Anhui Medical University (Hefei,
Anhui, People’s Republic of China) between 2001 and
2002. The details of this cohort have previously been
described in detail [5,19] including the definition of
human epidermal growth factor receptor-2 (HER-2)status according to the ASCO/CAP HER-2 Guideline
Recommendations [20]. Patients with BBD include 10
cases of fibroadenoma and 16 cases of adenosis. In MC
patients, there are 150 cases of invasive ductal carcin-
oma, 6 cases of invasive lobular carcinoma and 3 cases
of mucinous carcinoma. Among 159 MC patients, 126
patients were followed for a median follow-up time of
60 months (range 8–64 months). The protocol for the
use of patient samples in this study was approved by the
Institutional Review Board and patient consent forms
were obtained from all patients in accordance with the
Declaration of Helsinki.
Tissue microarrays (TMA) Construction
Paraffin-embedded BBD and MC specimens were
obtained from archive of the Department of Pathology,
the First Affiliated Hospital of Anhui Medical University,
P.R. China. TMAs were constructed as previously
described [21]. Three tissue “spots” from two different
paraffin blocks of each case of BBD and MC were
included per patient. The spot diameter for mammary
tissue was 1 mm. A total of five TMA blocks were pre-
pared and sectioned for in situ hybridization and immu-
nohistochemical analysis.
In situ hybridization (ISH)
Digoxin-labeled antisense oligonucleotide probes for
GFRα1, GFRα3 and SDC3 were obtained from Boshide
Biotech Co. (Wuhan, China). The probe sequences were
as follows:
GFRα1
50-TTCAT ATCAG ATGTT TTTCA GCAAG
TGGAG CACAT-30;
GFRα3
50-TGCCA CCGGC GCATG AAGAA CCAGG
TTGCC TGCTT-30,
50-CACTG CCAGC GCCAC GTCTG CCTCA
GGCAG CTGCT-30 and
50-GATTT CCAGA CCCAC TGCCA TCCCA
TGGAC ATCCT −30.
SDC3
50-CAGCG CTGGC GCAGT GAGAA CTTCG
AGAGA CCCGT-30 and
50-TACTT CGAGC AGGAG TCGGG CATTG
AGACA GCCAT −30
ISH was performed as described previously [19,22].
Briefly, 4 μm-thick TMA sections were deparaffinized,
rehydrated, and then digested with pepsin for 20 min at
37°C and refixed in 4% paraformaldehyde. After the sec-
tions were washed with PBS, hybridization solution was
placed on each section for 2 h and then replaced with
hybridization solution with probes (or scrambled probes
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washing with sodium chloride-sodium citrate (SSC), the
sections were incubated with an anti-digoxin antibody
followed by binding to streptavidin-biotin-peroxidase
complex solution. After that, the sections were stained
with 3, 3´-diaminobenzidine solution and counterstained
with hematoxylin solution.
Immunohistochemistry (IHC)
Immunohistochemical analysis of GFRα1, GFRα3 and
SDC3 protein expression was performed on TMA sec-
tions (4 μm thick) with polyclonal antibodies against
GFRα1(1:100 dilution; Santa Cruz Biotechnologies, Santa
Cruz, CA), GFRα3 (1:100 dilution; Santa Cruz Biotech-
nologies) and SDC3 (1:80 dilution; ProteinTech Group,
Chicago, IL) by the peroxidase-conjugated streptavidin
complex method (Histostain-SP Kit, Zymed, San Francisco,
CA) as previously described [5,19,22].
Review and scoring
The stained sections were reviewed and scored for ex-
pression of GFRα1, GFRα3 and SDC3 with a light
microscope (Olympus American Inc., Melville, NY) in-
dependently by two pathologists without knowledge of
the patient’s clinical or histopathological information as
previously described [5,19,22]. The rare cases with dis-
cordant scores were re-evaluated and scored on the basis
of consensual opinion. The sections were scored on the
basis of the staining intensity and the percentage of cells
with staining relative to the background [23]. The evalu-
ation of extent of staining was based on the percentage
of positive-stained tumor cells among all the tumor cells
in each case and classified into 4 categories: 0 (0%), 1
(1%-25%), 2 (26%-50%), 3 (51%-75%), and 4 (76%-100%).
The intensity of staining was based on the color intensity
of the tumor cells in each case and classified into 4
categories: 0 (negative), 1 (weak), 2 (medium), and 3
(strong). The sum of the intensity and extent score was
used as the final score (0–7). Tissue specimens having a
final score >2 were considered positive.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware system for Windows (version 13.0; SPSS, Chicago,
IL). The chi-squared (χ2) test was used to analyze theTable 1 Comparative expression of GFRα1, GFRα3 and SDC3 i
carcinoma (MC)
GFRα1 expression (n (%)) GFRα
Group n mRNA P protein P mRNA
BBD 26 6(23.1) 0.01 5(19.2) 0.067 5(19.2) 0
MC 159 80(50.3) 60(37.7) 68(42.8)
Values in bold are significant (P < 0.05).difference in the expression levels among different sam-
ples. The statistical significance of potential correlations
was determined using the χ2 test. Pearson’s correlation
coefficient was calculated to evaluate the relationships
between the expression of GFRα1, GFRα3 or SDC3 and
ARTN expression. Kaplan-Meier curves were con-
structed to determine patient relapse-free survival (RFS)
and overall survival (OS) rates. Cox regression analysis
was performed to determine the association of GFRα1,
GFRα3 and SDC3 expression to the risk of relapse and
death. The statistical differences in survival among sub-
groups were compared using the log-rank test. P values
< 0.05 were considered statistically significant.
Results
Expression of GFRα1, GFRα3 and SDC3 mRNA and protein
in benign breast disease and mammary carcinoma
We first utilized ISH to determine the expression of
GFRα1, GFRα3 and SDC3 mRNA in mammary tissue
from benign breast disease (BBD) and MC. GFRα1,
GFRα2 and SDC3 mRNA expression was observed in 6
(23.1%), 5 (19.2%) and 9 (34.6%) of the 26 BBD tissue
samples respectively. Weak or moderate expression of
GFRα1 and GFRα3 mRNA was observed in the cyto-
plasm of epithelial cells of mammary ducts and acini.
Moderate expression of SDC3 mRNA was observed in
mammary tissue and similarly localized in the cytoplasm
of the epithelium. In contrast to BBD, 80 (50.3%) and 68
(42.8%) of 159 MC specimens were positive for GFRα1
and GFRα3 mRNA respectively, which was a signifi-
cantly higher percentage than that observed in BBD tis-
sues (P = 0.010 and P = 0.023, Table 1). Moderate or
strong expression of GFRα1 and GFRα3 mRNA was pre-
dominantly localized in the carcinoma cells with an in-
frequently positive signal located in stromal cells
(Figure 1). As shown in Figure 1, the positive signal for
SDC3 mRNA was mainly localized in cytoplasm with in-
frequent expression in the nuclei of carcinoma cells in
MC tissue. However, the percentage expression of SDC3
mRNA was similar and non-significant between BBD and
MC tissues (positive rates of 35.8% and 34.6% (P = 0.903)
respectively, Table 1).
We next utilized IHC to determine the expression of
immunoreactive protein for GFRα1, GFRα3 and SDC3
in the same cohort of specimens. Although the IHCn benign breast disease (BBD) and mammary
3 expression (n (%)) SDC3 expression (n (%))
P protien P mRNA P protein P
.023 3(11.5) 0.037 9 (34.6) 0.903 8(30.8) 0.796
50(31.4) 57(35.8) 45(28.3)







   

















   









Figure 1 In situ hybridization and immunohistochemical analysis of GFRα1, GFRα3 and SDC3 mRNA and protein expression in benign
breast disease and mammary carcinoma. A, In situ hybridization analysis. Up, low expression of GFRα1 and GFRα3 mRNA and high expression
of SDC3 mRNA in mammary tissue derived from patients with benign breast disease; Bottom, high expression of GFRα1, GFRα3 and SDC3 mRNA
in mammary carcinoma. B, Immunohistochemistry. Up, low expression of GFRα1 and GFRα3 protein and high expression of SDC3 protein in
mammary tissue derived from patients with benign breast disease; Bottom, high expression of GFRα1, GFRα3 and SDC3 protein in mammary
carcinoma. All images are counterstained with hematoxylin. Photomicrographs were captured at 200X magnification.
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sion patterns of GFRα1, GFRα3 and SDC3 protein were
observed in the BBD and MC tissues as for mRNA expres-
sion. Pearson’s correlation analysis demonstrated a signifi-
cant association of expression of GFRα1 mRNA with both
GFRα1 and GFRα3 protein and a significant association of
GFRα3 mRNA with both GFRα1 and GFRα3 protein
(Additional file 1: Table S1). SDC3 mRNA was signifi-
cantly associated with SDC3 protein expression.
Similar to mRNA expression, GFRα1, GFRα3 and
SDC3 proteins were localized in the cytoplasm of epithe-
lial cells of mammary ducts and acini in BBD or carcin-
oma cells in MC. As shown in Table 1, 37.7% (n = 60)
and 31.4% (n = 50) of 159 MC specimens were positive
for GFRα1 or GFRα3 protein respectively, whereas only19.2% (n=5) and 11.5% (n=3) of 26 BBD specimens were
positive for GFRα1 or GFRα3 protein (P = 0.067 and
P = 0.037) respectively. Meanwhile, no significant differ-
ence of SDC3 protein expression was observed between
BBD and MC specimens (P = 0.796). The localization
of ARTN protein has previously been reported in this
cohort [5] and GFRα1, GFRα3 or SDC3 protein were
co-expressed with ARTN in 27.7% (n = 44), 25.2%
(n = 40) and 21.4% (n = 34) of MC samples respectively
(Additional file 1: Table S2). In 45.9% (n = 73) of MC
samples, co-expression of ARTN protein and any one of
its binding proteins GFRα1, GFRα3 or SDC3 was
observed (Additional file 1: Table S2). 36% (n = 57) of
MC samples were either GFRα1 or GFRα3 and ARTN
positive (Additional file 1: Table S2).
Table 2 Association of tumor GFRα1, GFRα3 and SDC3
mRNA expression with clinicopathologic parameters of










Parameter n mRNA P mRNA P mRNA P
Age (years)
≤ 35 16 14 (87.5) 0.005 11 (68.8) 0.043 8 (50.0) 0.399
35-55 92 45 (48.9) 40 (43.5) 33 (35.9)
> 55 51 21 (41.2) 17 (33.3) 16 (31.4)
Tumor size (cm)
≤ 2 13 6(46.2) 0.62 4 (30.8) 0.406 7 (53.8) 0.364
2 ~ 5 115 56 (48.7) 48 (417) 39 (33.9)
> 5 31 18 (58.1) 16 (51.6) 11 (35.5)
Histologic type
Ductal 150 78(52.0) 0.142 67(44.7) 0.127 54(36.0) 0.333
Lobular 6 2(33.3) 1(16.7) 1(16.7)
Mucinous 3 0(0) 0(0) 2(66.7)
Lymph node metastasis
0 55 20 (36.4) 0.013 19 (34.5) 0.235 23 (41.8) 0.481
1 ~ 3 55 28 (50.9) 24(43.6) 17 (30.9)
>3 49 32 (65.3) 25 (51.0) 17 (34.7)
Grade
I 13 8 (61.5) 0.436 6 (46.2) 0.678 7 (53.8) 0.124
II 102 53 (52.0) 41 (40.2) 31 (30.4)
III 44 19 (43.2) 21 (47.7) 19 (43.2)
Stage
I-II 85 32 (37.6) 0.001 32 (37.6) 0.162 31 (36.5) 0.861
III-IV 74 48 (64.9) 36(48.6) 26 (35.1)
ER status ^
- 94 49 (52.1) 0.582 37 (39.4) 0.297 31 (33.0) 0.364
+ 65 31 (47.7) 31 (47.7) 26 (40.0)
PR status ^^
- 90 44 (48.9) 0.681 36 (40.0) 0.421 27 (30.0) 0.079
+ 69 36 (52.2) 32 (46.4) 30 (43.5)
HER-2 *
- 121 53 (43.8) 0.003 47 (38.8) 0.074 44 (36.4) 0.809
+ 38 27 (71.1) 21 (55.3) 13 (34.2)
^ ER positive required at least 10% staining nuclei.
^^ PR positive required at least 10% staining nuclei.
HER-2 positive were 3+ or 2+ and FISH confirmed.
Values in bold are significant (P < 0.05).
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SDC3 and clinicopathologic features of mammary
carcinoma
Next, we investigated for any potential association of
tumor expression of mRNA or protein for GFRα1, GFRα3
and SDC3 with the clinicopathologic features of MC. As
observed in Table 2, expression of GFRα1 mRNA was sig-
nificantly associated with younger patient age (P = 0.005),
tumor lymph node metastasis (LNM) (P = 0.013), higher
clinical stage (P = 0.001) and HER-2 positive expression
(P = 0.002). The expression of GFRα3 mRNA was signifi-
cantly associated with younger patient age (P = 0.043). Sig-
nificant associations were also observed between the
protein expression of GFRα1 and GFRα3 and certain clini-
copathologic characteristics of MC. As observed in Table 3,
both the expression of GFRα1 and GFRα3 protein were
significantly associated with tumor LNM (P = 0.001 and
P = 0.006), higher clinical stage (P = 0.001 and P = 0.008)
and HER-2 positive expression (P = 0.030 and P = 0.005)
respectively. However, no significant association was
observed between SDC3 mRNA or protein expression
and any clinicopathologic characteristic (all P > 0.05).
Correlation between GFRα1, GFRα3, SDC3 and ARTN
expression
ARTN expression has also been implicated in disease
progression in the same cohort of MC specimens used
herein [5]. We therefore utilized correlation analysis to
determine the relationship between ARTN protein ex-
pression and the expression of GFRα1, GFRα3 or SDC3
proteins in the same cohort of MC patients. As observed
in Additional file 1: Table S1, Pearson’s correlation ana-
lyses revealed that the expression of ARTN protein was
significantly correlated to the protein expression of
GFRα3 (rs = 0.208, P = 0.009, respectively).
Correlation between GFRα1, GFRα3 and SDC3 expression
and patient survival
To determine the prognostic significance of GFRα1,
GFRα3 and SDC3 expression in patients with MC, we
firstly performed Kaplan-Meier analyses to correlate the
expression of these receptors for ARTN and patient re-
lapse free survival (RFS) and overall survival (OS). As
observed in Figure 2 and Additional file 1: Table S3,
patients whose tumors were positive for expression of
GFRα3 mRNA exhibited a lower 5 year RFS or OS rate
than patients whose tumors were negative for GFRα3
mRNA respectively (P = 0.008 and P = 0.030). Similarly,
expression of GFRα3 protein also predicted a lower 5
year RFS or OS than patients whose tumors were negative
for GFRα3 protein respectively (P = 0.002 and P = 0.011).
Patients whose tumors expressed GFRα1 protein (but not
GFRα1 mRNA) exhibited a significantly lower RFS and
OS compared to patients whose tumors were negative forGFRα1 protein respectively (P = 0.003 and P = 0.004). No
significant association was observed between tumor ex-
pression of SDC3 mRNA or protein and patient RFS or
OS (all P > 0.05).
We then examined for the effect of combined expres-
sion of these receptors on RFS and OS of patients with
Table 3 Association of tumor GFRα1, GFRα3 and SDC3
protein expression with clinicopathologic parameters of










Parameter n protein P protein P protein P
Age (years)
≤ 35 16 9 (56.3) 0.249 9 (56.3) 0.078 5 (31.3) 0.768
35-55 92 34 (37.0) 26 (28.3) 24 (26.1)
> 55 51 17 (33.3) 15 (29.4) 16 (31.4)
Tumor size (cm)
≤ 2 13 6 (46.2) 0.135 4 (30.8) 0.37 5 (38.5) 0.555
2 ~ 5 115 38 (33.0) 33 (28.7) 30 (26.1)
> 5 31 16 (51.6) 13 (41.9) 10 (32.3)
Histologic type
Ductal 150 57 (38.0) 0.142 49 (32.7) 0.352 41 (27.3) 0.313
Lobular 6 2 (33.3) 1 (16.7) 2 (33.3)
Mucinous 3 1 (33.3) 0 (0) 2 (66.7)
Lymph node metastasis
0 55 9 (16.4) 0.001 9 (16.4) 0.006 15 (27.3) 0.977
1 ~ 3 55 24 (43.6) 19 (34.5) 16 (29.1)
>3 49 27 (55.1) 22 (44.9) 14 (28.6)
Grade
I 13 6 (46.2) 0.657 4 (30.8) 0.906 4 (30.8) 0.788
II 102 36 (35.2) 31 (30.4) 27 (26.5)
III 44 18 (40.9) 15 (34.1) 14 (31.8)
Stage
I-II 85 19 (22.4) 0.001 19 (22.4) 0.008 23 (27.1) 0.709
III-IV 74 41 (55.4) 31 (41.9) 22 (29.7)
ER status^
- 94 39 (41.5) 0.24 27 (28.7) 0.374 24 (25.5) 0.351
+ 65 21 (32.3) 23 (35.4) 21 (32.3)
PR status^^
- 90 32 (35.6) 0.517 28 (31.1) 0.917 22 (24.4) 0.218
+ 69 28 (40.6) 22 (31.9) 23 (33.3)
HER-2 *
- 121 40 (33.1) 0.03 31 (25.6) 0.005 33 (27.3) 0.607
+ 38 20 (52.6) 19 (50.0) 12 (31.6)
^ ER positive required at least 10% staining nuclei.
^^ PR positive required at least 10% staining nuclei.
HER-2 positive were 3+ or 2+ and FISH confirmed.
Values in bold are significant (P < 0.05).
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tive for both GFRα1 and GFRα3 mRNA or protein were
significantly higher than patients whose tumors were
positive for mRNA or protein expression of both GFRα1
and GFRα3 (Additional file 1: Table S3). Moreover, the
RFS and OS rates for patients whose tumors werenegative for the mRNA for all the three ARTN receptors
were greatly and significantly higher compared to those
patients whose tumors were both GFRα1 mRNA and
SDC3 mRNA negative but GFRα3 positive (P = 0.002
and 0.001 respectively) (Additional file 1: Table S3).
Consistent with the results of the univariate Kaplan-
Meier survival analysis, multivariate analysis also
revealed that the adjusted odds ratios for death or re-
lapse of patients with MC were concordantly signifi-
cantly elevated in those patients whose tumors
expressed GFRα1 protein, GFRα3 mRNA or GFRα3 pro-
tein (Additional file 1: Table S4).
Correlation between GFRα1, GFRα3 and SDC3 expression
and patient survival in ER and HER2 subgroups
Given the previous reports of an association of the ex-
pression of GFRα1 and GFRα3 with ER expression [4]
and tamoxifen resistance in MC [24], we further exam-
ined for a potential association of GFRα1, GFRα3 and
SDC3 expression with RFS or OS in the subgroups of
patients with tumors with either ER negative or ER posi-
tive expression, or with differential expression of HER-2.
As shown in Additional file 1: Table S5, the expression
of GFRα1 and GFRα3 protein in patients with ER posi-
tive tumors tended to correlate with RFS, but did not
reach significance (P = 0.095 and 0.091). However, a sig-
nificant positive correlation was observed between the
expression of SDC3 protein and OS in patients with ER
positive tumors (P = 0.023, Additional file 1: Table S5).
In patients with ER negative tumors, the expression of
either GFRα1 or GFRα3 mRNA or protein was signifi-
cantly correlated with patient RFS and OS (Additional
file 1: Table S6). No significant correlation was observed
between SDC3 mRNA or protein expression and patient
survival (all P > 0.05) in ER negative MC.
We next performed Kaplan-Meier analysis of the ex-
pression of the different receptors for ARTN and patient
survival in the subgroups of patients with differential
HER-2 expression. The expression of GFRα1 and GFRα3
protein (but not SDC3 protein) was significantly asso-
ciated with decreased RFS and OS in HER-2 negative
MC. The expression of GFRα3 mRNA was significantly
associated with decreased RFS in HER-2 negative MC
whereas the expression of SDC3 mRNA was positively
and significantly associated with RFS in this subgroup
(Additional file 1: Table S7). Interestingly, no significant
correlation was observed between any of these three
receptors for ARTN and RFS or OS in patients with
HER2-positive tumors (Additional file 1: Table S8).
Co-expression of GFRα1 or GFRα3 with ARTN predicts
worse survival outcome
We next determined if co-expression of the ligand with
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Figure 2 Kaplan-Meier analysis of the significance of expression of GFRα1, GFRα3 and SDC3 mRNA and protein on relapse free survival
(RFS) and overall survival (OS) of patients with mammary carcinoma.
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Table 4 Association of tumor ARTN, GFRα1, GFRα3 and
SDC3 protein expression with five year relapse-free
survival (RFS) and overall survival (OS) in patients with
ER-positive/ER-negative or HER2-positive/HER2-negative
mammary carcinoma
RFS (%) P OS (%) P
ER-positive
ARTN-GFRα1-/ARTN + GFRα1+ 81.0/50.0 0.153 90.5/50.0 0.044
ARTN-GFRα3-/ARTN + GFRα3+ 81.8/50.0 0.199 86.4/50.0 0.138
ARTN- SDC3-/ARTN + SDC3+ 54.2/66.7 0.679 66.7/66.7 0.903
ER-negative
ARTN-GFRα1-/ARTN + GFRα1+ 76.0/16.7 0.002 84.0/16.7 0.001
ARTN-GFRα3-/ARTN + GFRα3+ 75.0/25.0 0.009 81.3/25.0 0.005
ARTN- SDC3-/ARTN + SDC3+ 71.4/50.0 0.532 71.4/50.0 0.532
HER2-positive
ARTN-GFRα1-/ARTN + GFRα1+ 75.0/100.0 0.605 87.5/100.0 0.724
ARTN-GFRα3-/ARTN + GFRα3+ NA NA
ARTN- SDC3-/ARTN + SDC3+ NA NA
HER2-negative
ARTN-GFRα1-/ARTN + GFRα1+ 78.9/22.2 0.001 86.8/22.2 0.001
ARTN-GFRα3-/ARTN + GFRα3+ 79.1/37.5 0.01 83.7/37.5 0.005
ARTN- SDC3-/ARTN + SDC3+ 64.3/60.0 0.855 71.4/60.0 0.679
Note: NA, not available.
Values in bold are significant (P < 0.05).
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a worse survival outcome for patients. Patients with
tumors that expressed both ARTN and GFRα1 or ARTN
and GFRα3, both by univariate and multivariate survival
analysis, exhibited a worse survival outcome than pa-
tients whose tumors did not express ARTN and GFRα1
or GFRα3, suggesting that patients with tumors that
were ARTN-positive and either GFRα1-positive or
GFRα3-positive had a poorer outcome than any other
phenotypes (Additional file 1: Table S9 and S10). Sur-
vival outcome in patients whose tumor expressed both
ARTN and SDC3 was not significantly different to those
patients who were negative for both proteins.
Co-expression of receptors with ARTN is associated with a
worse survival outcome in selected subgroups of
mammary carcinoma
We next determined if the worse survival outcome in
patients with tumors with co-expression of either GFRα1
or GFRα3 and ARTN was restricted to tumor subtypes.
We therefore examined for a potential association of the
expression of ARTN protein combined with GFRα1,
GFRα3 or SDC3 protein expression, with RFS or OS in
the subgroups of patients with tumors that are desig-
nated either ER negative or ER positive or HER-2 nega-
tive or HER-2 positive. Highly significant associations of
combined ARTN and GFRα1 or GFRα3 expression with
RFS or OS was observed in only the ER negative and
HER-2 negative subgroups (Table 4). There was no sig-
nificant association of combined ARTN and SDC3 expres-
sion with RFS or OS in the ER negative or HER-2 negative
subgroups. No association of expression in any combin-
ation of protein with either RFS or OS was observed in
the ER positive or HER-2 positive subgroups.
Discussion
Herein, we observed that two proteins, GFRα1 and
GFRα3, previously demonstrated to bind ARTN [3], are
expressed at significantly higher levels in MC compared
to BBD. In contrast, the expression of a third protein,
SDC3, also demonstrated to bind ARTN [18], was not
increased in expression in MC. Concordantly, the ex-
pression of GFRα1 and GFRα3 was also associated with
clinicopathologic features predicting a poor outcome,
such as lymph node metastases and tumor stage,
whereas the expression of SDC3 was not associated with
any such features. Moreover, both GFRα1 and GFRα3
were associated with poor survival outcome by univari-
ate and multivariate analyses whereas SDC3 was not.
Finally, co-expression of ARTN with either GFRα1 or
GFRα3 but not SDC3 produced synergistic increases in
the odds ratio for both RFS and OS in patients with MC.
Hence, it is apparent that GFRα1 or GFRα3 or combina-
tions of both mediate the described oncogenic effects ofARTN in both ER negative [11] or ER positive MC [14].
Whether these observations also apply to other
described ARTN sensitive cancers, such as pancreatic,
endometrial and lung carcinoma [7-9,25] remains to be
determined. It is also possible that further proteins that
bind ARTN are yet to be identified and may also partici-
pate in the oncogenic functions of ARTN in various can-
cer types. Indeed, GDNF has been demonstrated to bind
to and/or activate other oncogenic signaling mediators
such as MET [26], N-CAM [27] and integrins α5 and β3
[28,29]. In this regard it is interesting that ARTN was
co-expressed with GFRα1 or GFRα3 in only approxi-
mately 25% of cases respectively and with either GFRα1
or GFRα3 in 35.8% of cases. We previously demon-
strated that ARTN was expressed in 65.4% of tumors in
this cohort [5]. Thus, a significant portion of tumors ex-
press ARTN but not GFRα1 or GFRα3 suggestive that
alternative receptors for ARTN may be expressed in
these tumors. One other explanation is that a percentage
of tumors with ARTN expression may not functionally
respond to ARTN due to lack of expression of proteins
binding ARTN. ARTN sensitive cancers of varying origin
may also utilize different ARTN binding receptors, or
different combinations thereof, to promote tumor pro-
gression. However, other reports [25] have demonstrated
that the protein levels of both ARTN and GFRα3 were sig-
nificantly increased in pancreatic cancer compared to
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tive of potential co-ordinated increased expression al-
though this was not specifically determined. In any case,
our work herein suggests that expression of GFRα1 and/or
GFRα3, especially when combined with ARTN expression,
may be a useful predictor of disease progression and out-
come in MC.
Previous studies have examined the expression of
GFRα1 and RET in MC ([4,30]; for review see [31])
However, these studies did not examine potential corre-
lations of the expression of GFRα1 with survival out-
come nor the significance of co-expression of GFRα1
with GFRα3 nor ARTN. Concordant with our study
herein, Esseghir et al. [4] reported that expression of
GFRα1 mRNA was increased in MC compared with nor-
mal mammary tissue. Furthermore, and consistent with
our results, higher levels of GFRα1 mRNA were reported
to be associated with tumor lymphovascular invasion
and lymph node metastasis [4]. However, while Esseghir
et al. [4] reported that GFRα1 mRNA was associated
with both ER and PR status we failed to observe such a
correlation herein. The potential reasons for this dis-
crepancy are not apparent but could be due to differ-
ences in the material investigated, differences in the
visualization methods, evaluation scoring used in IHC
and ISH, or the heterogeneity of the disease. The patient
cohort utilized herein was entirely of Han Chinese ethni-
city whereas the cohort utilized by Esseghir et al. [4] was
sourced in the United Kingdom. We have however, pre-
viously described that ARTN is associated with ER status
[14], despite its expression in ER negative MC, and is es-
trogen regulated. Furthermore, RET has been reported
to be expressed preferentially in ER positive MC [32].
We have however described a clear metastasis promot-
ing role for ARTN in ER negative MC [11] consistent
with the association of GFRα1 and GFRα3 expression
with lymph node metastasis observed in this study. Fur-
thermore, significant associations of GFRα1 and GFRα3
expression with survival outcome observed herein was
restricted to ER negative MC. It should be noted that
autonomous expression of estrogen regulated genes are
often utilized in the transition from estrogen dependent
to estrogen independent growth of MC [33]. Consistent
with this notion, ARTN has been reported to promote
both estrogen independent growth of ER positive MC
cells and resistance to anti-estrogen therapy [14].
Conclusion
In this study, we demonstrate that expression of GFRα1 or
GFRα3, particularly in combination with ARTN, is asso-
ciated with worse survival outcome for patients, specific-
ally with ER negative and HER-2 negative MC. Expression
of these proteins may therefore be useful as prognostic
markers in certain subtypes of MC and for selection ofpatients where inhibition of ARTN is to be considered as a
therapeutic strategy. Whether ARTN also binds to other
proteins, as yet to be identified, to mediate its effects on
progression of MC remains to be determined.
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